Company intelligence / Profile preview
Fuji Yakuhin
Saitama-shi, Saitama, Japanfujiyakuhin.co.jp ↗
- Ownership
- Private
- Employees
- ~20563
- Development stage
- Commercial
01
Overview
Japanese pharmaceutical company with full-cycle operations from R&D to manufacturing, holding domestic market leadership in pharmaceutical distribution and operating over >1,200 drugstores. Developed dotinurad (URAT1 inhibitor) approved in Japan (2020) and licensed to Eisai for ASEAN/China markets[6][7].
- Therapeutic areas
- Women's HealthImmunologyMetabolic DisordersRheumatology
- Modalities
- Small moleculesSynthetic peptides
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Eisai Co., Ltd. (dotinurad licensing in China/ASEAN)[6]
Beyond the preview
Go deeper on Fuji Yakuhin.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fuji Yakuhin.